enGene Holdings Inc. Common Stock - Asset Resilience Ratio
enGene Holdings Inc. Common Stock (ENGN) has an Asset Resilience Ratio of 78.14% as of July 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ENGN net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how enGene Holdings Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ENGN total assets.
Liquid Assets Composition Over Time
This chart breaks down enGene Holdings Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of enGene Holdings Inc. Common Stock to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $225.29 Million | 78.14% |
| Total Liquid Assets | $225.29 Million | 78.14% |
Asset Resilience Insights
- Very High Liquidity: enGene Holdings Inc. Common Stock maintains exceptional liquid asset reserves at 78.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
enGene Holdings Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare enGene Holdings Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for enGene Holdings Inc. Common Stock (2023–2025)
The table below shows the annual Asset Resilience Ratio data for enGene Holdings Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-10-31 | 64.87% | $143.66 Million | $221.47 Million | +43.85pp |
| 2024-10-31 | 21.02% | $65.40 Million | $311.17 Million | +20.93pp |
| 2023-10-31 | 0.09% | $76.00K | $86.96 Million | -- |
About enGene Holdings Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. T… Read more